The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin.
Cardiovasc Diabetol
; 20(1): 150, 2021 07 23.
Article
in En
| MEDLINE
| ID: mdl-34301253
Full text:
1
Collection:
01-internacional
Health context:
6_ODS3_enfermedades_notrasmisibles
Database:
MEDLINE
Main subject:
Benzhydryl Compounds
/
Cytokines
/
Ventricular Function, Left
/
Inflammation Mediators
/
Myocytes, Cardiac
/
Sodium-Glucose Transporter 2 Inhibitors
/
Glucosides
/
Heart Diseases
Type of study:
Prognostic_studies
Limits:
Animals
Language:
En
Journal:
Cardiovasc Diabetol
Year:
2021
Document type:
Article